First-Line Treatment of Advanced Renal Cell Carcinoma With Oral Sunitinib

This clinical practice guideline discusses the use of oral sunitinib as first-line treatment in patients with advanced/metastatic renal cell carcinoma of clear-cell histology who have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 and who are of low to intermediate risk as defined by Memorial Sloan Kettering Cancer Centre (MSKCC) risk status. The guideline provides a treatment regimen and recommendations for clinical monitoring and follow-up care. Clinical toxicity assessment is discussed along with common or clinically important adverse events and drug interactions.